Cargando…
Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters
INTRODUCTION: Anti-Ro52/tripartite motif-containing protein 21 (TRIM21) IgG is one of the most common autoantibodies found in systemic autoimmune diseases and is typically found in conjunction with anti-Ro60 and/or anti-La. A retrospective, cross-sectional study was undertaken to examine the clinica...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568495/ https://www.ncbi.nlm.nih.gov/pubmed/35871174 http://dx.doi.org/10.1007/s10067-022-06299-5 |
_version_ | 1784809649153769472 |
---|---|
author | Lee, Adrian Y. S. Lin, Ming-Wei Reed, Joanne H. |
author_facet | Lee, Adrian Y. S. Lin, Ming-Wei Reed, Joanne H. |
author_sort | Lee, Adrian Y. S. |
collection | PubMed |
description | INTRODUCTION: Anti-Ro52/tripartite motif-containing protein 21 (TRIM21) IgG is one of the most common autoantibodies found in systemic autoimmune diseases and is typically found in conjunction with anti-Ro60 and/or anti-La. A retrospective, cross-sectional study was undertaken to examine the clinical and laboratory features of two serological subsets: patients with anti-Ro52/TRIM21 autoantibodies in the absence of anti-Ro60 and anti-La (isolated anti-Ro52/TRIM21) and patients with anti-Ro52/TRIM21 in the presence of anti-Ro60 and/or anti-La. METHODS: Over a 12-month period, patients tested positive for anti-Ro52/TRIM21 via line immunoassay (LIA) at the Westmead Hospital (Australia) immunopathology laboratory were included. The presence of anti-Ro60 and/or anti-La via same LIA was noted. Associated laboratory and medical records were perused to extract demographic, laboratory, and clinical information. RESULTS: There were 346 patients within the study period, and 39.9% of the patients positive for anti-Ro52/TRIM21 lacked anti-Ro60/anti-La autoantibodies. Isolated anti-Ro52/TRIM21 patients tend to be older, have lower anti-Ro52/TRIM21 titres, have lower rheumatoid factors, and have lower proportions of neutropaenia compared to patients who were positive for anti-Ro52/TRIM21 and anti-Ro60/La. This occurred independent to diagnoses of Sjögren’s syndrome or systemic lupus erythematosus. Coexisting neurological syndromes, pulmonary pathologies, and malignancies were more prevalent in the isolated anti-Ro52/TRIM21 subset. CONCLUSIONS: Patients with isolated anti-Ro52/TRIM21 tend to have distinct and important clinical and laboratory associations. It is unclear if these patients evolve or remain a stable subset and how they originate immunologically. Longitudinal and prospective studies are required to ascertain the overall predictive and prognostic value of this stratification. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-022-06299-5. |
format | Online Article Text |
id | pubmed-9568495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-95684952022-10-16 Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters Lee, Adrian Y. S. Lin, Ming-Wei Reed, Joanne H. Clin Rheumatol Original Article INTRODUCTION: Anti-Ro52/tripartite motif-containing protein 21 (TRIM21) IgG is one of the most common autoantibodies found in systemic autoimmune diseases and is typically found in conjunction with anti-Ro60 and/or anti-La. A retrospective, cross-sectional study was undertaken to examine the clinical and laboratory features of two serological subsets: patients with anti-Ro52/TRIM21 autoantibodies in the absence of anti-Ro60 and anti-La (isolated anti-Ro52/TRIM21) and patients with anti-Ro52/TRIM21 in the presence of anti-Ro60 and/or anti-La. METHODS: Over a 12-month period, patients tested positive for anti-Ro52/TRIM21 via line immunoassay (LIA) at the Westmead Hospital (Australia) immunopathology laboratory were included. The presence of anti-Ro60 and/or anti-La via same LIA was noted. Associated laboratory and medical records were perused to extract demographic, laboratory, and clinical information. RESULTS: There were 346 patients within the study period, and 39.9% of the patients positive for anti-Ro52/TRIM21 lacked anti-Ro60/anti-La autoantibodies. Isolated anti-Ro52/TRIM21 patients tend to be older, have lower anti-Ro52/TRIM21 titres, have lower rheumatoid factors, and have lower proportions of neutropaenia compared to patients who were positive for anti-Ro52/TRIM21 and anti-Ro60/La. This occurred independent to diagnoses of Sjögren’s syndrome or systemic lupus erythematosus. Coexisting neurological syndromes, pulmonary pathologies, and malignancies were more prevalent in the isolated anti-Ro52/TRIM21 subset. CONCLUSIONS: Patients with isolated anti-Ro52/TRIM21 tend to have distinct and important clinical and laboratory associations. It is unclear if these patients evolve or remain a stable subset and how they originate immunologically. Longitudinal and prospective studies are required to ascertain the overall predictive and prognostic value of this stratification. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-022-06299-5. Springer International Publishing 2022-07-23 2022 /pmc/articles/PMC9568495/ /pubmed/35871174 http://dx.doi.org/10.1007/s10067-022-06299-5 Text en © Crown 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Lee, Adrian Y. S. Lin, Ming-Wei Reed, Joanne H. Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters |
title | Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters |
title_full | Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters |
title_fullStr | Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters |
title_full_unstemmed | Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters |
title_short | Anti-Ro52/TRIM21 serological subsets identify differential clinical and laboratory parameters |
title_sort | anti-ro52/trim21 serological subsets identify differential clinical and laboratory parameters |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568495/ https://www.ncbi.nlm.nih.gov/pubmed/35871174 http://dx.doi.org/10.1007/s10067-022-06299-5 |
work_keys_str_mv | AT leeadrianys antiro52trim21serologicalsubsetsidentifydifferentialclinicalandlaboratoryparameters AT linmingwei antiro52trim21serologicalsubsetsidentifydifferentialclinicalandlaboratoryparameters AT reedjoanneh antiro52trim21serologicalsubsetsidentifydifferentialclinicalandlaboratoryparameters |